secwatch.observer — SEC 8-K summary
======================================

Issuer:     NKGen Biotech, Inc. (—)
CIK:        0001845459
Form:       8-K
Filed at:   2024-03-15T23:59:59+00:00
Accession:  0001104659-24-035067
Event type: regulatory
Sentiment:  negative
Materiality: 0.80
Item codes: 3.01
LLM model:  deepseek-v4-flash:cloud@v2

NKGen Biotech receives Nasdaq MVLS deficiency notice; 180-day cure period until Sep 9, 2024
--------------------------------------------------------------------------------

- Received Nasdaq Staff notice on March 11, 2024, for MVLS below $50M minimum for 30 consecutive business days.
- Must regain compliance by Sep 9, 2024; if MVLS >= $50M for 10 consecutive business days, notice will be closed.
- Company's market cap exceeded $50M on March 11, 2024 after the notice; evaluating actions to regain compliance.
- If not compliant by Sep 9, common stock may be delisted; company may appeal or apply to transfer to Nasdaq Capital Market.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1845459/000110465924035067/0001104659-24-035067-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1845459/000110465924035067/tm248953d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-035067

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer